Cardiovascular effects of native and non-native urotensin II and urotensin II-related peptide on rat and salmon hearts

Peptides

Volumn 27, Issue 12, 2006, Pages 3261-3268

  Prosser, H C G ^a,b   Leprince, J ^c   Vaudry, H ^c   Richards, A M ^b   Forster, M E ^a   Pemberton, C J ^b  

^a UNIVERSITY OF CANTERBURY   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c INSERM   (France)

Author keywords

Isolated rat heart; Salmon coronary arteries; Urotensin II; URP; Vasodilation

Indexed keywords

INDOMETACIN; N(G) NITROARGININE METHYL ESTER; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; UROTENSIN II; UROTENSIN II RELATED PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY CONSTRICTION; CORONARY ARTERY DILATATION; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; SALMON; STATISTICAL SIGNIFICANCE; TROUT;

ANIMALS; CORONARY VESSELS; MALE; MYOCARDIUM; PEPTIDE HORMONES; RATS; RATS, SPRAGUE-DAWLEY; SALMON; UROTENSINS;

CALLOGOBIUS ATRATUS; MAMMALIA; ONCORHYNCHUS TSHAWYTSCHA; SALMONIDAE;

EID: 33750956353     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2006.09.012     Document Type: Article

References (49)

1. Abdelrahman A.M., and Pang C.C.Y. Involvement of the nitric oxide/l-arginine and sympathetic nervous systems on the vasodepressor action of human urotensin II in anesthetized rats. Life Sci 71 (2002) 819-825
2. Agnisola C., Mustafa T., and Hansen J.K. Autoregulatory index, adrenergic responses, an interaction between adrenoreceptors and prostacyclin in the coronary vessels of rainbow trout. J Exp Biol 275 (1996) 239-248
3. Ames R.S., Sarau H.M., Chambers J.K., Willette R.N., Aiyar N.V., Romanic A.M., et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401 (1999) 282-286
4. Behm D.J., Harrison S.M., Ao Z., Maniscalco K., Pickering S.J., Grau E.V., et al. Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice. Br J Pharmacol 139 (2003) 464-472
5. Bottrill F.E., Douglas S.A., Hiley C.R., and White R. Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br J Pharmacol 130 (2000) 1865-1870
6. 2 may activate ATP sensitive potassium channels in the isolated rat heart. Cardiovasc Res 28 (1994) 901-905
7. Brkovic A., Hattenberger A., Kostenis E., Klabunde T., Flohr S., Kurz M., et al. Functional and binding characterizations of urotensin II-related peptides in human and rat urotensin II-receptor assay. J Pharmacol Exp Ther 306 (2003) 1200-1209
8. Chatenet D., Dubessy C., Leprince J., Boularan C., Carlier L., Ségalas-Milazzo I., et al. Structure-activity relationships and structural conformation of a novel urotensin II-related peptide. Peptides 25 (2004) 1819-1830
9. Cornish E.J., Goldie R.G., Krstew E.V., and Miller R.C. Effect of indomethacin on responses of sheep isolated coronary artery to arachidonic acid. Clin Exp Pharmacol Physiol 10 (1983) 171-175
10. Coulouarn Y., Jegou S., Tostivint H., Vaudry H., and Lihrmann I. Cloning, sequence analysis and tissue distribution of the mouse and rat urotensin II precursors. FEBS Lett 457 (1999) 28-32
11. Coulouarn Y., Lihrmann I., Jegou S., Anouar Y., Tostivint H., Beauvillain J.C., et al. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci USA 95 (1998) 15803-15808
12. Coy D.H., Rossowski W.J., Cheng B.-L., and Taylor J.E. Structural requirements at the N-terminus of urotensin II octapeptides. Peptides 23 (2002) 2259-2264
13. Douglas S.A., Sulpizio A.C., Piercy V., Sarau H.M., Ames R.S., Aiyar N.V., et al. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 131 (2000) 1262-1274
14. Forster M.E. Effects of catecholamines on the hearts and ventral aortas of the eels Anguilla australis schmidtii and Anguilla dieffenbachia. Comp Biochem Physiol C 70 (1981) 85-90
15. Gardiner S.M., March J.E., Kemp P.A., and Bennett T. Bolus injection of human UII in conscious rats evokes a biphasic haemodynamic response. Br J Pharmacol 143 (2004) 422-430
16. Gendron G., Gobeil F.J., Bélanger S., Gagnon S., Regoli D., and D'Orléans-Juste P. Urotensin II-induced hypotensive responses in Wistar-Kyoto (Wky) and spontaneously hypertensive (Shr) rats. Peptides 26 (2005) 1468-1474
17. Gray G.A., Jones M.R., and Sharif I. Human urotensin II increases coronary perfusion pressure in the isolated rat heart: potentiation by nitric oxide synthase and cyclooxygenase inhibition. Life Sci 69 (2001) 175-180
18. Hassan G.S., Chouiali F., Saito T., Hu F., Douglas S.A., Ao Z., et al. Effect of human urotensin-II infusion on hemodynamics and cardiac function. Can J Physiol Pharmacol 81 (2003) 125-128
19. Heller J., Schepke M., Neef M., Woitas R., Rabe C., and Sauerbruch T. Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension. J Hepatol 37 (2002) 762-772
20. Heringlake M., Kox T., Uzun O., Will B., Bahlmann L., Klaus S., et al. The relationship between urotensin II plasma immunoreactivity and left ventricular filling pressures in coronary artery disease. Regul Pept 121 (2004) 129-136
21. Hood S.G., Watson A.M.D., and May C.N. Cardiac actions of central but not peripheral urotensin II are prevented by β-adrenoceptor blockade. Peptides 26 (2005) 1248-1256
22. Horie S., Tsurumaki Y., Someya A., Hirabayashi T., Saito T., Okuma Y., et al. Involvement of cyclooxygenase-dependent pathway in contraction of isolated ileum by urotensin II. Peptides 26 (2005) 323-329
23. Ishihata A., Ogaki T., Aita T., and Katano Y. Role of prostaglandins in urotensin II-induced vasodilation in the coronary arteries of aged rats. Eur J Pharmacol 523 (2005) 119-126
24. Ishihata A., Ogaki T., Aita T., and Katano Y. Urotensin II-stimulated production of prostaglandins and nitric oxide in coronary arteries of aged rats. J Pharmacol Sci 97 (2005) 182P
25. Ishihata A., Sakai M., and Katano Y. Vascular contractile effect of urotensin II in young and aged rats: influence of aging and contribution of endothelial nitric oxide. Peptides 27 (2006) 80-86
26. Itoh H., Itoh Y., Rivier J., and Lederis K. Contraction of major artery segments of rat by fish neuropeptide urotensin II. Am J Physiol 252 (1987) R361-R366
27. Katano Y., Ishihata A., Aita T., Ogaki T., and Horie T. Vasodilator effect of urotensin II, one of the most potent vasoconstricting factors, on rat coronary arteries. Eur J Pharmacol 402 (2000) 209-211
28. Kinney W.A., Almond Jr. H.R., Qi J., Smith C.E., Santulli R.J., de Garavilla L., et al. Structure-function analysis of urotensin II and its use in the construction of a ligand-receptor working model. Angew Chem Int Ed 41 (2002) 2940-2944
29. Labarrère P., Chatenet D., Leprince J., Marionneau C., Loirand G., Tonon M.C., et al. Structure-activity relationships of human urotensin II and related analogues on rat aorta ring contraction. J Enz Inh Med Chem 18 (2003) 77-88
30. Lancien F., Leprince J., Mimassi N., Mabin D., Vaudry H., and Le Mevel J.-C. Central effects of native urotensin II on motor activity, ventilatory movements, and heart rate in the trout Oncorhynchus mykiss. Brain Res 1023 (2004) 167-174
31. Langham R.G., Kelly D.J., Gow R.M., Zhang Y., Dowling J.K., Thomson N.M., et al. Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy. Am J Kidney Dis 44 (2004) 826-831
32. Li L., Yuan W.-J., and Su D.-F. Effects of rat urotensin II on coronary flow and myocardial eNOS protein expression in isolated rat heart. Acta Pharmacol Sin 25 (2004) 1444-1449
33. Lihrmann I., Bern H.A., and Vaudry H. Urotensin II and urotensin II-related peptide. In: Kastin A.J. (Ed). Handbook of biologically active peptides (2006), Elsevier, New York 815-823
34. Lin L., Ding W.-H., Jiang W., Zhang Y.-G., Qi Y.-F., Yuan W.-J., et al. Urotensin-II activates l-arginine/nitric oxide pathway in isolated rat aortic adventitia. Peptides 25 (2004) 1977-1984
35. Liu Q., Pong S.-S., Zeng Z., Zhang Q., Howard A.D., Williams D.L.J., et al. Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. Biochem Biophys Res Commun 266 (1999) 174-178
36. Mori M., and Fujino M. Urotensin II-related peptide, the endogenous ligand for the urotensin II receptor in the rat brain. Peptides 25 (2004) 1815-1818
37. Mori M., Sugo T., Abe M., Shimomura Y., Kurihara M., Kitada C., et al. Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14). Biochem Biophys Res Commun 265 (1999) 123-129
38. Onan D., Hannan R.D., and Thomas W.G. Urotensin II: the old kid in town. Trends Endocrinol Metab 15 (2004) 175-182
39. Pearson D., Shively J.E., Clark B.R., Geschwind II, Barkley M., Nishioka R.S., et al. Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. Proc Natl Acad Sci USA 77 (1980) 5021-5024
40. Pemberton C.J., Raudsepp S.D., Yandle T.G., Cameron V.A., and Richards A.M. Plasma cardiotrophin-1 is elevated in human hypertension and stimulated by ventricular stretch. Cardiovasc Res 68 (2005) 109-117
41. Richards A.M., Nicholls M.G., Lainchbury J.G., Fisher S., and Yandle T.G. Plasma urotensin II in heart failure. Lancet 360 (2002) 545-546
42. Rossowski W.J., Cheng B.-L., Taylor J.E., Datta R., and Coy D.H. Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists. Eur J Pharmacol 438 (2002) 159-170
43. Russell F.D., Meyers D., Galbraith A.J., Bett N., Toth I., Kearns P., et al. Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. Am J Physiol Heart Circ Physiol 285 (2003) H1576-H1581
44. Russell F.D., and Molenaar P. Investigation of signaling pathways that mediate the inotropic effect of urotensin-II in human heart. Cardiovasc Res 63 (2004) 673-681
45. Sugo T., Murakami Y., Shimomura Y., Harada M., Abe M., Ishibashi Y., et al. Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain. Biochem Biophys Res Commun 310 (2003) 860-868
46. Totsune K., Takahashi K., Arihara Z., Sone M., Murakami O., Ito S., et al. Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with type 2 diabetes mellitus: association with progress of diabetic nephropathy. Peptides 25 (2004) 1809-1814
47. Totsune K., Takahashi K., Arihara Z., Sone M., Satoh F., Ito S., et al. Role of urotensin II in patients on dialysis. Lancet 358 (2001) 810-811
48. Watson A.M.D., Lambert G.W., Smith K.J., and May C.N. Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions. Hypertension 42 (2003) 373-379
49. Zhu Y.Z., Wang Z.J., Zhu Y.C., Zhang L., Oakley R.M.E., Chung C.W., et al. Urotensin II causes fatal circulatory collapse in anesthesized monkeys in vivo: a "vasoconstrictor" with a unique hemodynamic profile. Am J Physiol Heart Circ Physiol 286 (2004) H830-H836